Free Trial
NASDAQ:OMER

Omeros (OMER) Stock Price, News & Analysis

Omeros logo
$3.13 +0.05 (+1.62%)
As of 04:00 PM Eastern

About Omeros Stock (NASDAQ:OMER)

Key Stats

Today's Range
$3.06
$3.19
50-Day Range
$2.97
$7.35
52-Week Range
$2.95
$13.60
Volume
647,127 shs
Average Volume
727,216 shs
Market Capitalization
$183.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Moderate Buy

Company Overview

Omeros Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

OMER MarketRank™: 

Omeros scored higher than 66% of companies evaluated by MarketBeat, and ranked 279th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Omeros has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Omeros has only been the subject of 3 research reports in the past 90 days.

  • Read more about Omeros' stock forecast and price target.
  • Earnings Growth

    Earnings for Omeros are expected to grow in the coming year, from ($3.09) to ($1.73) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Omeros is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Omeros is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Omeros' valuation and earnings.
  • Percentage of Shares Shorted

    23.40% of the float of Omeros has been sold short.
  • Short Interest Ratio / Days to Cover

    Omeros has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Omeros has recently increased by 7.03%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Omeros does not currently pay a dividend.

  • Dividend Growth

    Omeros does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    23.40% of the float of Omeros has been sold short.
  • Short Interest Ratio / Days to Cover

    Omeros has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Omeros has recently increased by 7.03%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    Only 2 people have searched for OMER on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Omeros to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Omeros insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.90% of the stock of Omeros is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    48.79% of the stock of Omeros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Omeros' insider trading history.
Receive OMER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omeros and its competitors with MarketBeat's FREE daily newsletter.

OMER Stock News Headlines

Wall Street Zen Downgrades Omeros (NASDAQ:OMER) to Sell
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
See More Headlines

OMER Stock Analysis - Frequently Asked Questions

Omeros' stock was trading at $9.88 at the start of the year. Since then, OMER stock has decreased by 68.3% and is now trading at $3.13.

Omeros Corporation (NASDAQ:OMER) posted its quarterly earnings results on Thursday, May, 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by $0.05.
Read the conference call transcript
.

The following companies are subsidiaries of Omeros: Nura.

Shares of OMER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Omeros investors own include JPMorgan Chase & Co. (JPM), Visa (V), AbbVie (ABBV), Meta Platforms (META), NVIDIA (NVDA), QUALCOMM (QCOM) and Global X Nasdaq 100 Covered Call ETF (QYLD).

Company Calendar

Last Earnings
5/15/2025
Today
7/08/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:OMER
Employees
210
Year Founded
1994

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$36.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+484.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$156.82 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($3.15) per share
Price / Book
-0.98

Miscellaneous

Free Float
51,035,000
Market Cap
$180.46 million
Optionable
Optionable
Beta
2.16

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:OMER) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners